Vancouver, BC – February 20, 2014 – Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: FLU) wishes to announce that effective as the opening of trading of the Canadian Securities Exchange on Friday, February 21, 2014, the Company’s common shares will commence trading under the new stock symbol "ATT".
About Abattis Bioceuticals Corp.
Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. We follow strict Standard Operating Protocols and adhere to the Law’s of Canada and Foreign Jurisdictions. For more information, visit the Company’s website at www.abattis.com.
For further information, contact the Company’s CEO, Michael Withrow at (778) 896-6536 or at firstname.lastname@example.org.
ON BEHALF OF THE BOARD
President & CEO
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.